Supplementary Figures S1 - S2 from An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Authors:
  • AHAriella B. Hanker
    Ariella B. Hanker
  • MBMonica Red Brewer
    Monica Red Brewer
  • JSJonathan H. Sheehan
    Jonathan H. Sheehan
  • JKJames P. Koch
    James P. Koch
  • GSGregory R. Sliwoski
    Gregory R. Sliwoski
  • RNRebecca Nagy
    Rebecca Nagy
  • RLRichard Lanman
    Richard Lanman
  • MBMichael F. Berger
    Michael F. Berger
  • DHDavid M. Hyman
    David M. Hyman
  • DSDavid B. Solit
    David B. Solit
  • JHJie He
    Jie He
  • VMVincent Miller
    Vincent Miller
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S1. HER2L869R and HER3E928G cooperate to drive ERBB signaling output. Supplementary Figure S2. MG132 treatment restores expression of HER2T798I.